{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:46:29Z","timestamp":1781210789896,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.thromres.2021.05.021","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T02:00:25Z","timestamp":1622858425000},"page":"66-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Electrical impedance vs. light transmission aggregometry: Testing platelet reactivity to antiplatelet drugs using the MICELI POC impedance aggregometer as compared to a commercial predecessor"],"prefix":"10.1016","volume":"204","author":[{"given":"Tatiana","family":"Mencarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Roka-Moiia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Redaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Slepian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thromres.2021.05.021_bb0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2008.003178","article-title":"Platelet receptors and signaling in the dynamics of thrombus formation","volume":"94","author":"Rivera","year":"2009","journal-title":"Haematologica."},{"issue":"S 06","key":"10.1016\/j.thromres.2021.05.021_bb0010","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1160\/THS10-11-0720","article-title":"Platelets, inflammation and tissue regeneration","volume":"105","author":"Nurden","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.05.021_bb0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fimmu.2014.00649","article-title":"Platelets and infection - an emerging role of platelets in viral infection","volume":"5","author":"Assinger","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12865-015-0092-1","article-title":"Human platelets and their capacity of binding viruses: meaning and challenges?","volume":"16","author":"Chabert","year":"2015","journal-title":"BMC Immunol."},{"issue":"11","key":"10.1016\/j.thromres.2021.05.021_bb0025","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","article-title":"Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance","volume":"24","author":"Cattaneo","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"15","key":"10.1016\/j.thromres.2021.05.021_bb0030","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a high risk of recurrent cardiovascular events: a systematic review and meta-analysis","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.thromres.2021.05.021_bb0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation."},{"issue":"10","key":"10.1016\/j.thromres.2021.05.021_bb0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"07","key":"10.1016\/j.thromres.2021.05.021_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1160\/TH13-01-0057","article-title":"Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery","volume":"110","author":"Ferreiro","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041174","article-title":"The MICELI (MICrofluidic, ELectrical, impedance): prototyping a point-of-care impedance platelet aggregometer","volume":"21","author":"Roka-Moiia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10A","key":"10.1016\/j.thromres.2021.05.021_bb0055","doi-asserted-by":"crossref","first-page":"4N","DOI":"10.1016\/j.amjcard.2006.09.008","article-title":"Current options in platelet function testing","volume":"98","author":"Michelson","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2021.05.021_bb0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","article-title":"The aggregation of blood platelets","volume":"168","author":"Born","year":"1963","journal-title":"J. Physiol."},{"issue":"25","key":"10.1016\/j.thromres.2021.05.021_bb0070","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/blood-2012-07-444281","article-title":"Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel","volume":"120","author":"Dawood","year":"2012","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1538-7836.2009.03273.x","article-title":"Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments","volume":"7","author":"Hayward","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.05.021_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0160-5402(80)90024-8","article-title":"The electronic aggregometer: platelet behavior in blood a novel device for assessing key words","volume":"3","author":"Cardinal","year":"1980","journal-title":"J Pharmacol Methods"},{"issue":"9","key":"10.1016\/j.thromres.2021.05.021_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108589","article-title":"The role of whole blood impedance aggregometry and its utilisation in the diagnosis and prognosis of patients with systemic inflammatory response syndrome and sepsis in acute critical illness. Freson K, ed","volume":"9","author":"Davies","year":"2014","journal-title":"PLoS ONE"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2021.05.021_bb0090","article-title":"Comparison of multiple electrode impedance-based platelet aggregometry to light transmission aggregometry for diagnosis of qualitative platelet defects","volume":"130","author":"Mullins","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2021.05.021_bb0095","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1213\/ane.0b013e31818524c1","article-title":"Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study","volume":"107","author":"Velik-Salchner","year":"2008","journal-title":"Anesth. Analg."},{"issue":"3","key":"10.1016\/j.thromres.2021.05.021_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.thromres.2006.11.012","article-title":"Measuring antiplatelet drug effects in the laboratory","volume":"120","author":"Harrison","year":"2007","journal-title":"Thromb. Res."},{"issue":"16","key":"10.1016\/j.thromres.2021.05.021_bb0105","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/eurheartj\/ehp295","article-title":"Personalized medicine and antiplatelet therapy: ready for prime time?","volume":"30","author":"Verstuyft","year":"2009","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.thromres.2021.05.021_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129666","article-title":"Comparison of aggregometry with flow cytometry for the assessment of agonists\u00b4-induced platelet reactivity in patients on dual antiplatelet therapy. Hagemeyer CE, ed","volume":"10","author":"Gremmel","year":"2015","journal-title":"PLOS ONE"},{"issue":"8","key":"10.1016\/j.thromres.2021.05.021_bb0115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/jcp.2008.057174","article-title":"Platelet function testing: practice among UK National External Quality Assessment Scheme for blood coagulation participants, 2006","volume":"61","author":"Jennings","year":"2008","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.thromres.2021.05.021_bb0120","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/ejcts\/ezx181","article-title":"Postoperative bleeding in coronary artery bypass patients on double antiplatelet therapy: predictive value of preoperative aggregometry\u2020","volume":"52","author":"Della Corte","year":"2017","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"2","key":"10.1016\/j.thromres.2021.05.021_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-013-0105-2","article-title":"Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases","volume":"53","author":"Kara\u017aniewicz-\u0141Ada","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"08","key":"10.1016\/j.thromres.2021.05.021_bb0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1055\/s-0033-1333659","article-title":"The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery","volume":"61","author":"Schimmer","year":"2013","journal-title":"Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5482\/ha-1146","article-title":"Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives","volume":"31","author":"Seidel","year":"2011","journal-title":"Hamostaseologie."},{"issue":"6","key":"10.1016\/j.thromres.2021.05.021_bb0140","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jth.12231","article-title":"Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC\/ISTH","volume":"11","author":"Cattaneo","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.thromres.2021.05.021_bb0145","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.112.105908","article-title":"Guided antithrombotic therapy: current status and future research direction: report on a national heart, lung and blood institute working group","volume":"126","author":"Fuster","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2021.05.021_bb0150","unstructured":"Anon. U.S. Census Bureau QuickFacts: Pima County, Arizona. https:\/\/www.census.gov\/quickfacts\/fact\/table\/pimacountyarizona\/LND110210."},{"key":"10.1016\/j.thromres.2021.05.021_bb0155","article-title":"Desensitization of DMSO-treated platelets to common agonists via membrane modulation (598.5)","volume":"28:598.5","author":"Yamaguchi","year":"2014","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.thromres.2021.05.021_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1537-2995.1983.23283172844.x","article-title":"Dimethyl sulfoxide: effects on function of fresh platelets and on the viability of platelets in storage","volume":"23","author":"Fratantoni","year":"1983","journal-title":"Transfusion."},{"issue":"3","key":"10.1016\/j.thromres.2021.05.021_bb0165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0090-6980(86)90009-2","article-title":"Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man","volume":"32","author":"K\u00fcster","year":"1986","journal-title":"Prostaglandins."},{"key":"10.1016\/j.thromres.2021.05.021_bb0170","series-title":"Mechanism of Collagen Activation in Human Platelets*","author":"Roberts","year":"2004"},{"key":"10.1016\/j.thromres.2021.05.021_bb0175","series-title":"American College of Chest Physicians Evidence-based Clinical Practice Guidelines","first-page":"e89S","article-title":"Antiplatelet drugs - antithrombotic therapy and prevention of thrombosis","volume":"141(2 SUPPL.)","author":"Eikelboom","year":"2012"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2021.05.021_bb0180","first-page":"15","article-title":"Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects","volume":"25","author":"Savcic","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"issue":"19","key":"10.1016\/j.thromres.2021.05.021_bb0185","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","volume":"112","author":"Von Beckerath","year":"2005","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.thromres.2021.05.021_bb0190","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2021.05.021_bb0195","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1538-7836.2007.02598.x","article-title":"The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel\u2019s active metabolite","volume":"5","author":"SUGIDACHI","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral p2y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc. Ther."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0205","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2013.11.019","article-title":"Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients","volume":"7","author":"Rollini","year":"2014","journal-title":"J. Am. Coll. Cardiol. Intv."},{"issue":"7","key":"10.1016\/j.thromres.2021.05.021_bb0210","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/bph.13429","article-title":"Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines","volume":"173","author":"Nylander","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0215","first-page":"465","article-title":"P2Y12 receptor function and response to Cangrelor in neonates with cyanotic congenital heart disease","volume":"2","author":"Kaza","year":"2017","journal-title":"JACC: Basic to Translational Science."},{"issue":"3","key":"10.1016\/j.thromres.2021.05.021_bb0220","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/09537104.2015.1069809","article-title":"Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y 12 receptors in vitro","volume":"27","author":"Judge","year":"2016","journal-title":"Platelets."},{"key":"10.1016\/j.thromres.2021.05.021_bb0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2015.07.008","article-title":"Glycoprotein IIb\/IIIa inhibitors: the resurgence of tirofiban","volume":"78","author":"King","year":"2016","journal-title":"Vasc. Pharmacol."},{"issue":"9","key":"10.1016\/j.thromres.2021.05.021_bb0230","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1046\/j.1538-7836.2003.00349.x","article-title":"Different effects of various anti-GPIIB-IIIa agents on shear-induced platelet activation and expression of procoagulant activity","volume":"1","author":"Goto","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2021.05.021_bb0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1012991303381","article-title":"Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban","volume":"12","author":"Kereiakes","year":"2001","journal-title":"J. Thromb. Thrombolysis"},{"issue":"7","key":"10.1016\/j.thromres.2021.05.021_bb0240","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1074\/jbc.M211282200","article-title":"Red cell ICAM-4 is a novel ligand for platelet-activated \u03b1IIb\u03b23 integrin","volume":"278","author":"Hermand","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.thromres.2021.05.021_bb0245","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1111\/j.1432-1033.2004.04313.x","article-title":"Integrin receptor specificity for human red cell ICAM-4 ligand: critical residues for \u03b1IIb\u03b23 and \u03b1 v\u03b23 binding","volume":"271","author":"Hermand","year":"2004","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0250","first-page":"72","article-title":"New insights into the role of erythrocytes in thrombus formation","volume":"40","author":"Du","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"issue":"9","key":"10.1016\/j.thromres.2021.05.021_bb0255","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1172\/JCI92077","article-title":"Platelet-RBC interaction mediated by FasL\/FasR induces procoagulant activity important for thrombosis","volume":"128","author":"Klatt","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"16","key":"10.1016\/j.thromres.2021.05.021_bb0260","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1161\/CIRCULATIONAHA.106.675991","article-title":"Variable platelet response to aspirin and clopidogrel in atherothrombotic disease","volume":"115","author":"Maree","year":"2007","journal-title":"Circulation."},{"issue":"6","key":"10.1016\/j.thromres.2021.05.021_bb0265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00637504","article-title":"Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function","volume":"23","author":"Ross-Lee","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-2-1","article-title":"The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?","volume":"2","author":"Altman","year":"2004","journal-title":"Thromb. J."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042533313475576","article-title":"Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it","volume":"4","author":"Shahid","year":"2013","journal-title":"JRSM Short Reports."},{"issue":"3","key":"10.1016\/j.thromres.2021.05.021_bb0280","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","article-title":"Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin","volume":"5","author":"Guthikonda","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0285","first-page":"273","article-title":"Erythrocytes modulate the anti-aggregation effect of aspirin and dipyridamole. Study under static conditions and in a flow system","volume":"38","author":"Bozzo","year":"1993","journal-title":"Sangre (Barc)"},{"issue":"5","key":"10.1016\/j.thromres.2021.05.021_bb0290","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780250509","article-title":"Aspirin survival in human blood modulated by the concentration of erythrocytes","volume":"25","author":"Costello","year":"1982","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood.V78.1.154.154","article-title":"Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment","volume":"78","author":"Valles","year":"1991","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0300","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2008.02915.x","article-title":"Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease","volume":"6","author":"Santos","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2021.05.021_bb0305","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood.V99.11.3978","article-title":"Platelet-erythrocyte interactions enhance \u03b1IIb\u03b23 integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo","volume":"99","author":"Vall\u00e9s","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2021.05.021_bb0310","series-title":"Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in anti-platelet therapy","author":"Rondina","year":"2012"},{"issue":"11","key":"10.1016\/j.thromres.2021.05.021_bb0315","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1253\/circj.CJ-08-0289","article-title":"Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation","volume":"72","author":"Yamamoto","year":"2008","journal-title":"Circ. J."},{"issue":"6","key":"10.1016\/j.thromres.2021.05.021_bb0320","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0049-3848(00)00415-1","article-title":"Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol","volume":"101","author":"Kariyazono","year":"2001","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2021.05.021_bb0325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00001721-200403000-00007","article-title":"Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood","volume":"15","author":"Kariyazono","year":"2004","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"11","key":"10.1016\/j.thromres.2021.05.021_bb0330","first-page":"3978","article-title":"Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: Down-regulation by aspirin ex vivo","volume":"99","author":"Valles","year":"2002","journal-title":"Platelet-Erythrocyte interactions View project Euthanasia View project"},{"issue":"1","key":"10.1016\/j.thromres.2021.05.021_bb0335","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood.V78.1.154.154","article-title":"Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment","volume":"78","author":"Valles","year":"1991","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.thromres.2021.05.021_bb0340","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2008.02915.x","article-title":"Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease","volume":"6","author":"Santos","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2021.05.021_bb0345","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI115032","article-title":"Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment","volume":"87","author":"Santos","year":"1991","journal-title":"J. Clin. Investig."},{"issue":"18","key":"10.1016\/j.thromres.2021.05.021_bb0350","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1182\/blood-2012-05-427856","article-title":"Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation","volume":"120","author":"Whelihan","year":"2012","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.thromres.2021.05.021_bb0355","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.thromres.2013.01.023","article-title":"The role of the red cell membrane in thrombin generation","volume":"131","author":"Whelihan","year":"2013","journal-title":"Thromb. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821003625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821003625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:45:45Z","timestamp":1758735945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821003625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":71,"alternative-id":["S0049384821003625"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.05.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrical impedance vs. light transmission aggregometry: Testing platelet reactivity to antiplatelet drugs using the MICELI POC impedance aggregometer as compared to a commercial predecessor","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}